Abstract |
Noninfectious uveitis is a common blinding eye disease, and an autoimmune response is involved in its pathogenesis. Biological agents have gradually been introduced into the treatment of noninfectious uveitis. The authors reviewed the clinical application and side effects of different biological agents on noninfectious uveitis. Biological agents that target TNF-α are widely used in the clinic. Other biological agents, such as IL-6- and IL-1-neutralizing antibodies, are used in patients who do not respond to TNF inhibitors. The efficacy of IL-17 neutralizing antibodies in noninfectious uveitis is controversial. Biological agents targeting T cells and signaling pathways provide new drug options for treatment of noninfectious uveitis. However, it cannot be ignored that these biological agents have side effects, such as increasing risk of infection.
|
Authors | Bowen Li, Li Yang, Feng Bai, Bainan Tong, Xiaoli Liu |
Journal | Immunotherapy
(Immunotherapy)
Vol. 14
Issue 12
Pg. 985-994
(08 2022)
ISSN: 1750-7448 [Electronic] England |
PMID | 35695019
(Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Neutralizing
- Biological Factors
- Immunosuppressive Agents
- Tumor Necrosis Factor-alpha
|
Topics |
- Antibodies, Neutralizing
- Autoimmunity
- Biological Factors
(therapeutic use)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Tumor Necrosis Factor-alpha
- Uveitis
(drug therapy, etiology)
|